Department of Urology, Ajou University School of Medicine, Suwon, Korea.
Department of Urology, Bundang Jesaeng Hospital, Seongnam, Korea.
Int Neurourol J. 2014 Sep;18(3):145-9. doi: 10.5213/inj.2014.18.3.145. Epub 2014 Sep 24.
In this study, we examined the difference in the treatment efficacy depending on the sympathetic activity in men with lower urinary tract symptoms (LUTS).
In the current single-center, retrospective study, we evaluated a total of 66 male patients aged 40-70 years of age, presenting with LUTS, whose International Prostate Symptom Score (IPSS) exceeded 8 points. They had a past 3-month history of taking alfuzosin XL, and their heart rate variability (HRV) was measured before and after the treatment. In addition, we also recruited 39 healthy volunteers who visited a health promotion center for a regular medical check-up. They were aged between 40 and 70 years and had an IPSS of <8 points. We divided the patients with LUTS into two groups: the groups A and B, based on a low frequency/high frequency (LF/HF) ratio of 1.7, which was the mean value of the LF/HF ratio in the healthy volunteers. After a 3-month treatment with alfuzosin XL, we compared treatment outcomes, based on the IPSS and peak urine flow rate, between the two groups.
A 3-month treatment with alfuzosin XL, comprising the measurement of the HRV, was performed for the 23 patients of the group A (23/38) and 17 of the group B (17/28). After a 3-month treatment with alfuzosin XL, total IPSS and IPSS questionnaire 2 and 5 were significantly lower in the group A as compared with the group B. But this was not seen in the group B. Furthermore, there were no significant differences in other parameters, such as maximal flow rate and IPSS storage subscore, between the two groups.
Our results indicate that the treatment efficacy was lower in patients with sympathetic hyperactivity as compared with those with sympathetic hypoactivity. Thus, our results will provide a basis for further studies to clarify causes of LUTS in a clinical setting.
在这项研究中,我们考察了男性下尿路症状(LUTS)患者中交感神经活性差异对治疗效果的影响。
在目前这项单中心、回顾性研究中,我们共评估了 66 例年龄在 40-70 岁之间、有 LUTS 病史且国际前列腺症状评分(IPSS)>8 分的男性患者。他们均有近 3 个月服用阿夫唑嗪 XL 的病史,在治疗前后测量了心率变异性(HRV)。此外,我们还招募了 39 名年龄在 40-70 岁之间、因常规健康检查而到健康促进中心就诊的健康志愿者,他们的 IPSS<8 分。我们根据健康志愿者的 LF/HF 比值的平均值 1.7 将 LUTS 患者分为 A 组和 B 组。A 组(23/38)和 B 组(17/28)各有 23 例和 17 例患者接受了阿夫唑嗪 XL 治疗 3 个月。我们比较了两组患者的治疗结局,包括 IPSS 和最大尿流率。
A 组的 23 例(23/38)和 B 组的 17 例(17/28)患者接受了包含 HRV 测量的阿夫唑嗪 XL 治疗 3 个月。与 B 组相比,A 组患者在接受阿夫唑嗪 XL 治疗 3 个月后,总 IPSS 和 IPSS 问卷 2 和 5 显著降低。但 B 组患者未见上述情况。此外,两组间最大尿流率和 IPSS 储存分项评分等其他参数均无显著差异。
我们的结果表明,与交感神经活性低下的患者相比,交感神经活性亢进的患者治疗效果较低。因此,我们的结果将为进一步研究提供依据,以明确交感神经活性在临床环境中导致 LUTS 的原因。